John P. Walker
Chief Executive Officer
John P. Walker has served as a member of our board of directors since May 2016. Mr. Walker currently serves as Executive Chairman and Interim Chief Executive Officer of Vizuri Health Sciences, LLC and was most recently a Managing Director of Four Oaks Partners, a life sciences transaction advisory firm. His past positions included Chairman and Chief Executive Officer roles at Novacea, Kai Pharmaceuticals, Renovis, Axys Pharmaceuticals, Microcide, Signal Pharmaceuticals and other life sciences companies. Mr. Walker is a graduate of the Advanced Executive Program at The Kellogg School of Management at Northwestern University and holds a B.A. from the State University of New York at Buffalo.
Chief Business Officer, CFO
Georgia Erbez, our Chief Business Officer and Chief Financial Officer, joined Zosano in September 2016. Ms. Erbez previously consulted to Zosano as Interim CFO from June 2016 to September 2016. Prior to Zosano, Ms. Erbez provided strategic consulting and interim financial management services to several public and private biotechnology companies. Previously, she served as CFO, Secretary, and Treasurer to Raptor Pharmaceuticals from 2012 to 2014. She was a key member of the management team that guided Raptor through a growth phase including first drug approval and commercial drug launch. Prior to Raptor, Ms. Erbez spent over 20 years as an investment banker focused on advising and raising capital for emerging growth life sciences companies. She was a founder of Beal Advisors and held senior positions at Collins Stewart, Jeffries & Company, Inc. and Cowen and Company. She has also held positions of increasing responsibility at Hambrecht & Quist and Alex, Brown & Sons Inc. Ms. Erbez was awarded a Bachelor of Arts degree, International Relations from the University of California at Davis.
Donald Kellerman, PharmD
VP, Clinical Development and Medical Affairs
Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.
Senior Vice President, Operations
Hayley Lewis has recently been appointed our Senior Vice President Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015. Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 8 investigational products to be studied in humans, 5 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.